Caplin Steriles gets USFDA EIR

| Updated on July 25, 2019

Caplin Steriles, a wholly-owned subsidiary of Caplin Point Laboratories, has received the Establishment Inspection Report from the US Food and Drug Administration for the recently concluded inspection in June. This was the third successful US FDA audit of the plant since 2016, the company said in a statement to the exchanges. Shares of Caplin Point jumped 10.30 per cent at ₹425.80 on the BSE.

Published on July 25, 2019

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor